Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sanofi In-Licenses Three Diabetes Drugs from Korea's Hanmi in $4.2 Billion Deal

publication date: Nov 5, 2015
Sanofi of France has finalized an agreement to in-license global rights to three long-acting diabetes drugs from Hanmi Pharma of Korea in a deal worth $4.2 billion. Hanmi will receive $435 million upfront and up to $3.8 billion in milestones plus royalties on sales. Hanmi is on a roll. Earlier this year, the company out-licensed a novel lung cancer therapeutic to Boehringer Ingelheim for $730 million and sold the rights for an autoimmune drug to Lilly for $690 million. Hanmi retained the right to co-promote the three long-acting diabetes drugs with Sanofi in Korea and China. More details....

Stock Symbols: (NYSE: SNY) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital